Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10407781 | 0.74 | PDE10A (0.36) | DGAT1PDE10AEGLN2MKNK1DYRK1A | |
| SCHEMBL15739266 | 0.73 | PDE10A (0.35) | DGAT1PDE10AEGLN2MKNK1 | |
| SCHEMBL902753 | 0.73 | PDE10A (0.35) | DGAT1PDE10AMEN1KMT2AEGLN2 | |
| SCHEMBL21138821 | 0.73 | DGAT1 (0.42) | DGAT1PDE10AEGLN2MKNK1 | |
| SCHEMBL2991637 | 0.73 | PDE10A (0.35) | DGAT1PDE10AEGLN2MKNK1 | |
| SCHEMBL4572140 | 0.73 | DGAT1 (0.37) | DGAT1POLBPDE10AALDH1A1MEN1 | |
| SCHEMBL859975 | 0.73 | PDE10A (0.53) | DGAT1PDE10AEGLN2MKNK1AKT1 | |
| SCHEMBL10407034 | 0.73 | PDE10A (0.35) | DGAT1PDE10AEGLN2MKNK1 | |
| SCHEMBL20484514 | 0.72 | DGAT1 (0.36) | DGAT1PDE10A | |
| SCHEMBL5411017 | 0.71 | DGAT1 (0.41) | DGAT1PDE10AEGLN2MKNK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899187-A | Synthesis method of pyrazolo [1,5-a ] pyrimidine-7-amine compound | 湖南九典制药股份有限公司 | 2025-04-29 | — | — | CN | claimed |
| EP-4028131-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2023-11-22 | — | — | EP | claimed |
| EP-2621926-A2 | PYRAZOLOPYRIMIDINE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | claimed |
| EP-2051963-B1 | PROCESS FOR RESOLVING CHIRAL PIPERIDINE ALCOHOL AND PROCESS FOR SYNTHESIS OF PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES USING SAME | SCHERING CORP (US) | 2012-05-16 | — | — | EP | claimed |
| WO-2012044562-A2 | PYRAZOLOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | claimed |
| US-8076479-B2 | useful as cyclin-dependent kinase inhibitor compounds; minimizes the need for chromatographic purification of intermediates, and utilizes fewer changes of solvent systems | SCHERING CORPORATION (US) | 2011-12-13 | — | — | US | claimed |
| US-7786306-B2 | Process for resolving chiral piperidine alcohol and process for synthesis of pyrazolo[1,5-a] pyrimidine derivatives using same | SCHERING CORPORATION (US) | 2010-08-31 | — | — | US | claimed |
| EP-2057166-A2 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF (3-ALKYL-5-PIPERIDIN-1-YL-3,3A-DIHYDRO- PYRAZOLOÝ1,5-A¨PYRIMIDIN-7-YL)-AMINO DERIVATIVES AND INTERMEDIATES | SCHERING CORPORATION (US) | 2009-05-13 | — | — | EP | claimed |
| EP-2051963-A1 | PROCESS FOR RESOLVING CHIRAL PIPERIDINE ALCOHOL AND PROCESS FOR SYNTHESIS OF PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES USING SAME | SCHERING CORPORATION (US) | 2009-04-29 | — | — | EP | claimed |
| WO-2008027220-A2 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF (3-ALKYL-5-PIPERIDIN-1-YL-3, 3A-DIHYDROPYRAZOL0 [1, 5-A] PYRIMIDIN-7-YL) -AMINO DERIVATIVES | SCHERING CORPORATION (US) | 2008-03-06 | — | — | WO | claimed |
| US-20080058518-A1 | Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates | MERCK SHARP & DOHME LLC | 2008-03-06 | — | — | US | claimed |
| US-20080051579-A1 | Process for resolving chiral piperidine alcohol and process for synthesis of pyrazolo[1,5-a] pyrimidine derivatives using same | MERCK SHARP & DOHME LLC | 2008-02-28 | — | — | US | claimed |
| WO-2008021509-A1 | PROCESS FOR RESOLVING CHIRAL PIPERIDINE ALCOHOL AND PROCESS FOR SYNTHESIS OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES USING SAME | SCHERING CORPORATION (US) | 2008-02-21 | — | — | WO | claimed |
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4282868-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE DERIVATIVE, AND COMPOSITIONS AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20260027096-A1 | PHD INHIBITORS | UNIV OXFORD INNOVATION LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| EP-0771803-A1 | Pyrazolo(1,5-a)pyrimidinium substituted cephem derivatives, their preparation and their use as antimicrobial agents | KATAYAMA SEIYAKUSYO CO. Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
| EP-0714898-A1 | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-06-05 | — | — | EP | disclosed |
| US-4066644-A | CNS DEPRESSANTS, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-4066643-A | CNS DEPRESSANTS, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027096-A1 | PHD INHIBITORS | HIF1AN, HIF1A, EGLN1 | DGAT1 1945/4885POLB 3867/4885CHEK1 3278/4885 |
| US-20080051579-A1 | Process for resolving chiral piperidine alcohol and process for synthesis of pyrazolo[1,5-a] pyrimidine derivatives using same | ADH1C, ADH1A, ADH5 | DGAT1 612/4885POLB 393/4885CHEK1 2226/4885 |
| US-20080058518-A1 | Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates | CDK3, CDK7, CDK2 | DGAT1 3448/4885POLB 373/4885CHEK1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.